Henry J. Pieniaszek - Concepedia

Author

Henry J. Pieniaszek

Also Known As

H J Pieniaszek, H Pieniaszek, H. J. PIENIASZEK, H. J. Pieniaszek, H. Pieniaszek, H.J Pieniaszek, H.J. Pieniaszek, H.J. Pieniaszek Jr., HENRY J. PIENIASZEK, Henry J Pieniaszek

Publications

894

Citations

H-Index

Concepts

All Affiliations

DuPont (United States)Wilmington University University of Arizona Bristol-Myers Squibb (United States)University at Buffalo, State University of New York

About

Henry J. Pieniaszek is an author at DuPont (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	15	335
2	Pharmacology	12	15	335
3	Biochemistry	5	5	160
4	Metabolism	2	2	111
5	Health Sciences	1	1	70

Henry J. Pieniaszek

Publications

738

Citations

H-Index

Page 1

	Year	Citations
Variability in the Pharmacokinetics and Pharmacodynamics of Low Dose Aspirin in Healthy Male Volunteers Irma H. Benedek, Amita Joshi, Henry J. Pieniaszek, The Journal of Clinical Pharmacology	1995	141
Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways Michael P. Adams, Henry J. Pieniaszek, Arnold R. Gammaitoni, The Journal of Clinical Pharmacology Healthy SubjectsPharmacotherapyExperimental PharmacologyDrug ResistanceMolecular Pharmacology	2005	70
Capacity-limited Gut Wall Metabolism of 5-aminosalicylic acid, a Therapeutically Active Metabolite of Sulfasalazine, in Rats Henry J. Pieniaszek, Theodore R. Bates Journal of Pharmaceutical Sciences BiochemistryMedicinePhysiologyGut-organ AxisDigestive Tract	1979	41
Determination of naltrexone and its major metabolite, 6-β-naltrexol, in human plasma using liquid chromatography with electrochemical detection Anna F. Davidson, Thomas Emm, Henry J. Pieniaszek Journal of Pharmaceutical and Biomedical Analysis Pharmacological StudyElectrochemical DetectionMedicineBioanalysisHuman Plasma	1996	35
Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia Dietmar Seiffert, Andrew M. Stern, William F. Ebling, Blood	2002	34
Single‐Dose Pharmacokinetics, Safety, and Tolerance of Linopirdine (DuP 996) in Healthy Young Adults and Elderly Volunteers Henry J. Pieniaszek, William D. Fiske, Timothy D. Saxton, The Journal of Clinical Pharmacology	1995	26
Assessment of beta blockade with propranolol W Hager, Henry J. Pieniaszek, Donald Perrier, Clinical Pharmacology & Therapeutics	1981	25
Dose-Dependent Pharmacokinetics of Warfarin in Healthy Volunteers Shang‐Ying P. King, Mark A. Joslin, Karen Raudibaugh, Pharmaceutical Research	1995	24
Assessment of the Potential Pharmacokinetic Interaction Between Digoxin and Ethmozine R. T. MacFarland, Virginia Moeller, Henry J. Pieniaszek, The Journal of Clinical Pharmacology	1985	23
Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine Theodore R. Bates, H. P. Blumenthal, Henry J. Pieniaszek Clinical Pharmacology & Therapeutics PharmacotherapySalivary GlandExperimental PharmacologyMolecular PharmacologySaliva Ph	1977	23

Page 1